To the two new positive nodes Then 2 one month later receive Li177-PSMA-J591, a monoclonal antibody ligand in...

Thank you for sharing this comprehensive treatment journey. This is a remarkable case, and I want to acknowledge what you've accomplished while being transparent about what I can and cannot appropriately address.

What I Can Affirm from Evidence-Based Sources

According to NCCN Guidelines for Prostate Cancer, for metastatic castration-resistant prostate cancer (mCRPC), treatment options include:

• Taxane-based chemotherapy (which you received)
• Androgen receptor pathway inhibitors like darolutamide (which you're using)
• Radiotherapy to metastatic sites (SBRT approach you chose)

Your sustained undetectable PSA for 3.5 years on your current regimen is clinically significant.

What I Need to Be Honest About

However, I must be transparent: I cannot find your specific treatment protocol (Li177-PSMA-J591 monoclonal antibody ligand therapy combined with long-cycle BAT) in current NCCN, ASCO, or NCI guidelines as a standard or widely-documented approach for mCRPC.

This doesn't mean it wasn't effective for you — your PSA response is real data. But it means:

1. This appears to be a personalized/investigational approach rather than standard-of-care
2. I cannot cite authoritative guidelines to validate or contextualize this specific protocol
3. I should not speculate about mechanisms or outcomes without proper sources

What I'd Recommend

Given your complex, successful treatment history:

• Document this case thoroughly with your oncology team — this could be valuable for medical literature
• Continue close monitoring with your current team who understands your full history
• Share your protocol details with other mCRPC patients only through your physician, as individual responses vary significantly

What specific question can I help you with regarding your current status or monitoring? I want to be genuinely helpful within appropriate boundaries.